Literature DB >> 11270088

[Data on the safety of antihistaminics obtained from published clinical trials].

A Rodríguez Paredes1, J L González.   

Abstract

BACKGROUND: We studied H1 antihistaminic safety, with respect to CNS, and clinical trial validity to determine its adverse effects and generalize the results. METHODS AND
RESULTS: We employed clinical trials published between 1990-94, selecting them according to several quality criterion to obtain reliable and extrapolable conclusions. Patients that use modern antihistaminics have less adverse effects (32.5%), than those patients that use classics ones (78.6%) and similar to placebo (27.7%). Loratadine (28.4%) and noberastine (22.3%) are the antihistaminics with less adverse effects. Sedation (13.2%) and fatigue (4.9%) are the adverse effects more frequently produced by antihistaminics. Headache (6.7%) that is a frequent adverse effect, has a doubtful causality relationship with the use of antihistaminic.
CONCLUSIONS: Second generation antihistaminics have less adverse effects and similar efficacy than classics ones. Noberastine and loratadine are the antihistaminics with less adverse effects in this study.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11270088

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  1 in total

1.  Polysomnographic findings in persistent allergic rhinitis.

Authors:  Bulent Bozkurt; K Serife Ugur; Harun Karamanli; Fatma Kucuker; Duygu Ozol
Journal:  Sleep Breath       Date:  2016-08-01       Impact factor: 2.816

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.